Pliant Therapeutics, Inc. (NASDAQ:PLRX) Expected to Earn Q3 2024 Earnings of ($1.00) Per Share

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities researchers at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Pliant Therapeutics in a research report issued on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the company will earn ($1.00) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.69) per share. Leerink Partnrs also issued estimates for Pliant Therapeutics’ Q4 2024 earnings at ($0.98) EPS, FY2024 earnings at ($3.69) EPS, FY2025 earnings at ($3.84) EPS and FY2026 earnings at ($3.55) EPS.

Pliant Therapeutics (NASDAQ:PLRX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.07).

Several other research analysts have also recently commented on PLRX. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research note on Thursday, August 8th. HC Wainwright lifted their price target on shares of Pliant Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Leerink Partners began coverage on shares of Pliant Therapeutics in a research note on Monday. They set an “outperform” rating and a $33.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Pliant Therapeutics in a research report on Thursday, August 8th. Finally, Oppenheimer reduced their price target on shares of Pliant Therapeutics from $48.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $40.57.

Pliant Therapeutics Price Performance

Shares of PLRX stock opened at $12.98 on Wednesday. Pliant Therapeutics has a twelve month low of $10.29 and a twelve month high of $19.62. The company has a debt-to-equity ratio of 0.08, a quick ratio of 14.47 and a current ratio of 14.47. The firm has a fifty day simple moving average of $12.75 and a 200-day simple moving average of $13.23.

Insider Transactions at Pliant Therapeutics

In other news, CEO Bernard Coulie sold 38,710 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $11.56, for a total transaction of $447,487.60. Following the completion of the transaction, the chief executive officer now owns 482,936 shares of the company’s stock, valued at $5,582,740.16. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Bernard Coulie sold 38,710 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total transaction of $447,487.60. Following the completion of the transaction, the chief executive officer now directly owns 482,936 shares in the company, valued at $5,582,740.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Lefebvre sold 12,319 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total value of $142,407.64. Following the completion of the transaction, the insider now directly owns 213,052 shares of the company’s stock, valued at $2,462,881.12. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 69,596 shares of company stock worth $804,530. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pliant Therapeutics

Several institutional investors have recently bought and sold shares of PLRX. Quest Partners LLC bought a new stake in shares of Pliant Therapeutics during the 4th quarter worth about $37,000. Summit Securities Group LLC bought a new position in Pliant Therapeutics during the 2nd quarter valued at $59,000. SG Americas Securities LLC acquired a new position in shares of Pliant Therapeutics during the 1st quarter valued at $107,000. Deerfield Management Company L.P. Series C bought a new stake in shares of Pliant Therapeutics in the 2nd quarter worth $126,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Pliant Therapeutics by 67.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,581 shares of the company’s stock valued at $173,000 after buying an additional 4,652 shares in the last quarter. Institutional investors and hedge funds own 97.30% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.